Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-05-10
2011-05-10
Vivlemore, Tracy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07939503
ABSTRACT:
Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.
REFERENCES:
patent: 5624803 (1997-04-01), Noonberg et al.
patent: 6329503 (2001-12-01), Afar et al.
patent: 2002/0022248 (2002-02-01), Xu et al.
patent: 2003/0045682 (2003-03-01), Afar et al.
patent: 2003/0060612 (2003-03-01), Goddard et al.
patent: 2003/0064397 (2003-04-01), Spancake et al.
patent: 2005/0208039 (2005-09-01), Jakobovits et al.
patent: 0 834 563 (1998-04-01), None
patent: 1308459 (2003-05-01), None
patent: 11164691 (1999-06-01), None
patent: WO 94/09150 (1994-04-01), None
patent: WO9514772 (1995-06-01), None
patent: WO9514772 (1995-06-01), None
patent: WO 98/18489 (1998-05-01), None
patent: WO 98/37093 (1998-08-01), None
patent: WO 98/37418 (1998-08-01), None
patent: WO 98/53071 (1998-11-01), None
patent: WO9853071 (1998-11-01), None
patent: WO 99/06548 (1999-02-01), None
patent: WO 99/06550 (1999-02-01), None
patent: WO 99/61469 (1999-02-01), None
patent: WO9906548 (1999-02-01), None
patent: WO9906550 (1999-02-01), None
patent: WO 99/62941 (1999-12-01), None
patent: WO9962941 (1999-12-01), None
patent: WO9962941 (1999-12-01), None
patent: WO 00/04149 (2000-01-01), None
patent: WO0004149 (2000-01-01), None
patent: WO 00/35937 (2000-02-01), None
patent: WO0035937 (2000-06-01), None
patent: WO0077021 (2000-12-01), None
patent: WO 01/12662 (2001-02-01), None
patent: WO0112662 (2001-02-01), None
patent: WO0125272 (2001-04-01), None
patent: WO0134802 (2001-05-01), None
patent: WO0140276 (2001-06-01), None
patent: WO0140276 (2001-06-01), None
patent: WO0151633 (2001-07-01), None
patent: WO0157190 (2001-08-01), None
patent: WO0157276 (2001-08-01), None
patent: WO0157277 (2001-08-01), None
patent: WO0160860 (2001-08-01), None
patent: WO 01/72962 (2001-10-01), None
patent: WO0172962 (2001-10-01), None
patent: WO0173032 (2001-10-01), None
patent: WO0175067 (2001-10-01), None
patent: WO0186003 (2001-11-01), None
patent: WO0194629 (2001-12-01), None
patent: WO0196388 (2001-12-01), None
patent: WO 02/16429 (2002-02-01), None
patent: WO0210449 (2002-02-01), None
patent: WO 02/26822 (2002-04-01), None
patent: WO0230268 (2002-04-01), None
patent: WO02057303 (2002-07-01), None
patent: WO02059260 (2002-08-01), None
patent: WO02095010 (2002-11-01), None
patent: WO02102993 (2002-12-01), None
patent: WO02102994 (2002-12-01), None
patent: WO03004622 (2003-01-01), None
patent: WO03009814 (2003-02-01), None
patent: WO 03/022995 (2003-03-01), None
patent: WO 2005/113601 (2005-12-01), None
patent: WO 2006/034488 (2006-03-01), None
Bass Nature 2001, vol. 411, pp. 428-429.
Elbashir et al. EMBO Journal 2001, vol. 20, pp. 6877-6888.
International Search Report mailed on Apr. 28, 2003, for PCT patent application No. PCT/US02/28371 filed on Sep. 6, 2002, 1 page.
Haverstick et al., Cancer Research (2000) pp. 1002-1008.
Diss et al., FEBS Letters (1998) 427:5-10.
Grimes and Djamgoz, Journal of Cellular Physiology (1998) 175:50-58.
Skryma et al., The Prostate (1997) 33:112-122.
Gutierrez et al., Journal of Physiology (1999) 517.1:95-107.
Lepple-Wienhues et al., J. Membrane Biol. (1996) 151:149-157.
Marino et al., Tumor Biol. (1994) 15:82-89.
Pancrazio et al., Cancer Research (1989) 49:5901-5906.
Nie et al., Cell Calcium (1997) 22(2):75-82.
Database EMBL Nucleotide and Protein Sequences, Aug. 25, 1996, XP002128081, AA032221, Hinxton, GB.
Database EMBL Nucleotide and Protein Sequences, May 1, 1999, XP002128083, O95034 (clone RG041D11), Hinxton, GB.
Database EMBL Nucleotide and Protein Sequences, Jun. 15, 1998, XP002128084, AC004969 (clone DJ1121E10), Hinxton, GB.
Database EMBL Nucleotide and Protein Sequences, May 13, 1997, XP002128082, AC002064, Hinxton, GB.
Abu-Threideh et al., EMBL/GENBANK/DDBJ Databases, Jun. 1998.
Abu-Threidah et al., GENBANK, (Accession No. 095034), National Library of Medicine, Bethesda MD, May 1, 1999.
Herbert et al., The Dictionary of Immunology, Academic Press, 4th edition, 1995.
Greenspan et al., Nature Biotechnology (1999) 7:936-937.
Duclert et al., Genbank, (Accession No. Y11840), National Library of Medicine, Bethesda MD, Feb. 11, 1999.
Cate et al., GENBANK, (Accession No. W86309), National Library of Medicine, Bethesda MD, Nov. 1998.
Gura, Science (1997) 278:1041-1042.
Spitler, Cancer Biotherapy (1995) 10:1-3.
Lal et al., US Patent No. 6,048,970, May 1998, USPTO database sequence listing.
Bellone et al., Immunology Today (1999) 20(10):457-462.
Alberts et al., Molecular Biology of the Cell, 3rd edition, 1994, p. 465.
Shantz and Pegg, Int. J. of Biochem. and Cell Biol. (1999) 31:107-122.
McClean and Hill, Eur. J. of Cancer (1993) 29:2243-2248.
Fu et al., EMBO Journal (1996) 15:4392-4401.
Database EMBL “Human BAC clone CTB-167B5 from 7q21, complete sequence,” Jun. 17, 1998, XP002173859 (Accession AC 003991 Waterstone, R.).
Hubert et al., PNAS USA (1999) 96(25):14523-14528.
Burgess et al., Jnl. Cell Bio. (1990) 111:2129-2138.
Lazar et al., Mol. Cell Bio. (1988) 8(3):1247-1252.
Bowie et al., Science (1990) 247:1306-1310.
Rieger et al., Glossary of Genetics and Cytogenetics, Springer-Verlag 1976, p. 17.
International Search Report mailed on May 11, 2004, for PCT patent application No. PCT/US03/18661 filed on Jun. 11, 2003, 3 pages.
Challita-Eid Pia M., et al., “Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo”, vol. 67, No. 12, pp. 5798-5805, (2007).
Faris M., et al., “Validation of STEAP-1 as a cell surface cancer therapeutic target”, Proceedings of the annual meeting of the American Association for Cancer Research, vol. 43, p. 947, (2002).
Bantounas, I. et al., “RNA interference and the use of small interfering RNA to study gene function in mammalian systems,” (2004) J. Mol. Endocrinol. 33:545-557 (2004).
Kurreck, J., “siRNA efficiency: structure or sequence—that is the question,” J. Biomed. Biotechnol. 2006:1-7 (2006).
Hillier, et al., “The WashU-Merck EST Project,” EMBL Sequence Database, XP002128081, Aug. 25, 1996.
“WUGC:H—RG041D11.1 Protein (WUGSC: H—DJ1121E10.1 Protein) (Fragment),” EMBL Sequence Database, XP002128083, May 1, 1999.
“Homo sapiensPAC Clone DJ1121E10 from 7q21.1-q2, Complete Sequence,” EMBL Sequence Database, XP002128084, Jun. 15,1998.
“Human BAC Clone RG016J04 from 7q21, Complete Sequence,” EMBL Sequence Database, XP002128082, May 13, 1997.
Challita-Eid Pia M.
Etessami Soudabeh
Faris Mary
Gudas Jean
Jakobovits Aya
Agensys, Inc.
Dreger Ginger R.
Kresnak Mark T.
Popp Shane M.
Vivlemore Tracy
LandOfFree
Reduction of cell-cell communication in prostate cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reduction of cell-cell communication in prostate cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reduction of cell-cell communication in prostate cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2695832